Shots:

• The first patient has been enrolled in a P-IIb trial to evaluate HZN-825 (300mg, qd, bid) vs PBO in a ratio (1:1:1) in 360 patients with IPF for 52wks. The trial is based on the P-IIa trial in patients with early dcSSc
• The 1EP of the trial is changed in FVC after 52wks. & 2EPs include the 6MWT, K-BILD Questionnaire, rate of hospitalization due to respiratory distress, and a composite EPs of PFS
• HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. In the P-IIa trial, the result from the 16wk. open-label extension period showed benefit, 79% showed an improvement in mRSS who received 24wks. of treatment

Ref: Businesswire | Image: Horizon